Empowering the People Who Dedicate Their Lives to Microbiology

Thermo Fisher Scientific™ is at the forefront of the global response to coronavirus, working with; governments, agencies, industry partners and researchers globally, to ensure priority access to instruments, consumables, safety supplies and other products to address the outbreak.

Clinical microbiology laboratories have seen an influx of additional tests to identify viral and bacterial infections presenting similar symptoms to coronavirus. Identification of coronavirus as well as similar or related infections is vital to rapidly address the outbreak.

Within Clinical Microbiology we have focused on increasing our manufacturing capacity to deliver viral collection kits and transport media globally. As well as continuing to supply our microbial isolation and identification products and our Antimicrobial Susceptibility Testing (AST) range to maintain antibiotic stewardship even when faced with a pandemic.

Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP)

While data is still emerging, reports have suggested that 15% of hospitalized coronavirus patients developed a secondary bacterial infection, the definition of which is: clinical symptoms or signs of pneumonia or bacteraemia with positive culture¹.

Among patients who died from coronavirus, 16% of patients had secondary infections².

Sample collection, transport, identification and accurate treatment is vital to reducing patients' time in hospital and ultimately saving lives.

The ATCC Licensed Derivative Emblem, the ATCC Licensed Derivative word mark and the ATCC catalog marks are trademarks of ATCC. Remel Inc. is licensed to use these trademarks and to sell products derived from ATCC® cultures. The identity, purity, and authenticity of the Licensed Products are exclusively the responsibility of Remel Inc., and not ATCC.

References

1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 11[Online ahead of print].

​2. Ruan, Q., Yang, K., Wang, W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med (2020). https://doi.org/10.1007/s00134-020-05991-x